Ultragenyx Pharmaceutical (RARE) Enterprise Value (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Enterprise Value of -$406.0 million for Q1 2026, up 16.7% year-over-year from -$347.9 million in Q1 2025, and up 39.67% quarter-over-quarter from -$673.0 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Enterprise Value (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Enterprise Value for 14 consecutive years, with -$406.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 16.7% year-over-year to -$406.0 million; the TTM figure through Mar 2026 stood at -$406.0 million (up 16.7% YoY), while the FY2025 annual figure was -$673.0 million, down 11.61% from the prior year.
- Enterprise Value advanced to -$406.0 million in Q1 2026 per RARE's latest filing, from -$673.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$135.8 million in Q4 2022 and bottomed at -$888.7 million in Q3 2022.
- Historically, Enterprise Value has averaged -$521.5 million across 5 years, with a median of -$542.8 million in 2022.
- Annual changes were most pronounced in 2022 — Enterprise Value soared 58.37% — and 2024, when it slumped 177.62%.
- Ultragenyx Pharmaceutical's Enterprise Value stood at -$135.8 million in 2022, then sank by 60.0% to -$217.2 million in 2023, then plunged by 177.62% to -$603.0 million in 2024, then decreased by 11.61% to -$673.0 million in 2025, then surged by 39.67% to -$406.0 million in 2026.
- Business Quant data shows RARE's Enterprise Value at -$406.0 million in Q1 2026, -$673.0 million in Q4 2025, and -$418.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | -285.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -285.00 Mn |
| Mar 31, 2026 | -406.00 Mn |
| Dec 31, 2025 | -673.00 Mn |
| Sep 30, 2025 | -418.25 Mn |
| Jun 30, 2025 | -480.59 Mn |
| Mar 31, 2025 | -487.39 Mn |
| Dec 31, 2024 | -603.00 Mn |
| Sep 30, 2024 | -614.61 Mn |
| Jun 30, 2024 | -763.82 Mn |
| Mar 31, 2024 | -412.08 Mn |
| Dec 31, 2023 | -217.20 Mn |
| Sep 30, 2023 | -442.09 Mn |
| Jun 30, 2023 | -551.98 Mn |
| Mar 31, 2023 | -629.35 Mn |
| Dec 31, 2022 | -135.75 Mn |
| Sep 30, 2022 | -888.68 Mn |
| Jun 30, 2022 | -542.80 Mn |
| Mar 31, 2022 | -598.32 Mn |
| Dec 31, 2021 | -326.09 Mn |
| Sep 30, 2021 | -737.12 Mn |